23andMe cuts 40% of its workforce and discontinues therapeutics division
NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe on Monday.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
The restructuring arrives during a period of turmoil at the company that has included a high-profile data breach and several rounds of previous layoffs.
23andMe announces layoffs, will cut 40% of workforce
The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs. In a press release on Monday,
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
23andMe lays off 40% of workers, reports losses amid uncertain future
( NewsNation) — Genetic testing company 23andMe has faced a series of struggles this year, culminating in end-of-year mass ...
23andMe customer? Here's what to know about the privacy of your genetic data.
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
ABC 7 Chicago5h
What 23andMe business troubles could mean for users' genetic data
In this photo illustration, a 23andMe logo seen displayed on a smartphone and in the background. The company announced ...
23andMe says it faces financial hardships and has doubts it can still operate
The CEO of 23andMe said there was "substantial doubt" that the company could continue to operate and said 40 percent of its ...
23andMe is ending its cancer research program and slashing over 200 jobs
23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...
NBC Los Angeles2d
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The ...
Yahoo1d
23AndMe to lay off 40% of staff
The genealogy company’s CEO announced over 200 employees will be let go and it will also shutter its drug-development arm. I ...